Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HER2-negative breast cancer that has spread to other parts of the body and to the brain.
- You must have at least one brain tumor that can be measured on an MRI scan.
- You must be 18 years or older and able to care for yourself (ECOG score 0 or 1).
- You must have had no more than 3 prior chemotherapy treatments for advanced breast cancer.
- You must not have certain other medical conditions like uncontrolled seizures, bleeding problems, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
This trial tests a new chemotherapy combination (utidelone plus capecitabine) versus a standard taxane plus capecitabine for HER2-negative breast cancer. The goal is to see if the new combo works better and has fewer side effects.
This trial tests a new combination of two drugs (utidelone and bevacizumab) for people with advanced non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can control the brain tumors and slow down the disease.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
This trial compares an oral capsule form of the experimental drug Utidelone with the standard injection form, in people with HER2-negative advanced breast cancer. The goal is to see if the capsule works as well as the injection and is safe to use.
Hear when a new HER2-negative Breast Cancer Patients With Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.